China’s Growing Influence Is Reshaping the Global Biotech Industry

China is quickly emerging as an integral part of the biotechnology landscape across the globe, presenting the United States with an array of possibilities and challenges. On the one hand, U.S. pharmaceutical firms are depending on collaboration, innovations, and clinical tests carried out in China for developing drugs. But, on the other hand, the government of the country has become wary of the security implications of these ties.

This discussion has grown more heated lately when the members of the Congress have wondered whether further cooperation with China might endanger research work, intellectual property, and information of patients. But the representatives of the industry warn that severing these relations without building up America's biotech capabilities can lead to slower innovation and higher costs of making drugs.

Congress Raises National Security Concerns

The new debate comes after letters that were sent by John Moolenaar, who is the chair of the House Select Committee on China, to the CEOs of several major drug companies such as Eli Lilly, Pfizer, Merck, Bristol Myers Squibb, and AbbVie.

The committee is seeking an explanation from the companies on how they keep sensitive research protected when doing hundreds of clinical trials in China. The legislators are especially concerned with the research done in the military hospitals of China and the Xinjiang province of China.

The committee is seeking detailed explanations on data security, research supervision, and due diligence, as there are growing concerns that biotech would be seen as a matter of national security rather than a commercial business.

Why Drug Companies Continue to Invest in China

Although the pharmaceutical business is under greater political pressure now, China still provides opportunities for the sector.

During the last ten years, China has been developing its capacities in biotechnologies, laboratories and clinical trials. The reason why more and more drug manufacturers prefer China lies in the possibility to perform early-phase trials faster and cheaper compared to most countries.

In addition, China is becoming a source of breakthrough drugs. Recently, the global pharmaceutical companies entered into billions of deals regarding licensing of new technologies with the Chinese biotech companies.

From the point of view of the pharmaceutical sector, such collaborations represent a smart way to increase speed of innovation and competitiveness in the fast-changing global market environment.

Government Focuses on Reducing Dependence

A number of moves have been made by the U.S. government in order to decrease its dependence on the Chinese biotechnology sector.

In particular, the approval of the BIOSECURE Act is one of the key steps undertaken to address the issue. Even though the bill is not as strict as the previously introduced drafts, a lot of pharmaceutical firms have already started to change their suppliers of services due to it.

Other government initiatives, such as investigations into the import of pharmaceuticals and talks about imposing additional tariffs, reflect the general strategy adopted by Washington.

Industry Calls for Greater Investment Instead of Restrictions

Most biotechnology industry executives do not believe that restrictions alone will solve the issue.

Industry executives claim that if the policymakers want businesses to do more research in the United States, then they need to provide an attractive environment for research. Some recommendations for the U.S. government would be making the review process faster, building infrastructure for clinical trials, increasing government grants for research, and providing incentives for innovation.

FDA is already developing new initiatives for speeding up research in the early stages of clinical development, and the Department of Health and Human Services is trying to develop measures to make the United States more competitive in this regard. The industry believes that such an approach will work much better than imposing restrictions.

Finding the Right Balance for the Future

On this note, both the policymakers and the biotech industry agree that the U.S should continue leading in the life sciences field.

The disagreement between them comes from the way to reach such an end. The first one focuses on the protection of their national security and the minimization of risks linked with China, whereas the second one focuses on the maintenance of innovation and partnerships around the globe.

With increasing biotech capacities in China, the task of the U.S is to find a way between the protection of their own interests and scientific cooperation.